KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Sales (2016 - 2025)

NovoCure (NVCR) has disclosed Return on Sales for 12 consecutive years, with 0.14% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 27.0% to 0.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.21% through Dec 2025, up 7.0% year-over-year, with the annual reading at 0.21% for FY2025, 7.0% up from the prior year.
  • Return on Sales hit 0.14% in Q4 2025 for NovoCure, up from 0.22% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.03% in Q1 2021 to a low of 0.46% in Q2 2023.
  • Historically, Return on Sales has averaged 0.24% across 5 years, with a median of 0.22% in 2024.
  • Biggest five-year swings in Return on Sales: tumbled -40bps in 2023 and later grew 27bps in 2025.
  • Year by year, Return on Sales stood at 0.2% in 2021, then tumbled by -46bps to 0.29% in 2022, then decreased by -21bps to 0.35% in 2023, then fell by -16bps to 0.41% in 2024, then skyrocketed by 66bps to 0.14% in 2025.
  • Business Quant data shows Return on Sales for NVCR at 0.14% in Q4 2025, 0.22% in Q3 2025, and 0.25% in Q2 2025.